Effects of ALX5407 on thermal hyperalgesia: Behavioral tests with the Plantar Test (Ugo Basile, Comerio, Italy) in all five groups that received continuous systemic administration of the glycine transporter 1 inhibitor ALX5407 (Sigma-Aldrich^®, St. Louis, MO) (0.2, 2, 20, or 200 μg/kg per day, dissolved in (2-hydroxypropyl)-β-cyclodextrin) or vehicle. The line graphs show paw-withdrawal latencies (s) as response to a thermal stimulus from the injured left (A) and uninjured right paw (B) over time during application. Data are presented as mean ± SEM (n = 6). An asterisk indicates a significant difference compared with vehicle controls (P < 0.05).